Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Universitaire Ziekenhuizen KU Leuven
With
AstraZeneca
Age
18–100
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
with recurrent epithelial carcinoma of the ovary, fallopian tube or primary peritoneum
At least 1 previous line of chemotherapy
Measurable disease
Patients have a normal organ and bone marrow function measured within 28 days of randomization
WHO 0-2
You may not be if
Primary platinum-refractory disease
Known hypersensitivity to olaparib
Resting ECG with QTc \> 470 msec
Concomitant use of known potent CYP3A4 inhibitors
Symptomatic uncontrolled brain metastases
Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
Clareo Health | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
